Label Expansion And New Trials Will Fuel US Dermatology Demand
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
05 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$6.38
85.4% undervalued intrinsic discount15 Aug
US$0.93
1Y
-33.6%7D
1.4%